CO2021013371A2 - Compuestos y métodos para reducir la expresión de kcnt1 - Google Patents
Compuestos y métodos para reducir la expresión de kcnt1Info
- Publication number
- CO2021013371A2 CO2021013371A2 CONC2021/0013371A CO2021013371A CO2021013371A2 CO 2021013371 A2 CO2021013371 A2 CO 2021013371A2 CO 2021013371 A CO2021013371 A CO 2021013371A CO 2021013371 A2 CO2021013371 A2 CO 2021013371A2
- Authority
- CO
- Colombia
- Prior art keywords
- compounds
- methods
- kcnt1
- reduce
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962819344P | 2019-03-15 | 2019-03-15 | |
| US201962884501P | 2019-08-08 | 2019-08-08 | |
| PCT/US2020/022680 WO2020190740A1 (en) | 2019-03-15 | 2020-03-13 | Compounds and methods for reducing kcnt1 expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021013371A2 true CO2021013371A2 (es) | 2021-10-20 |
Family
ID=72520445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0013371A CO2021013371A2 (es) | 2019-03-15 | 2021-10-06 | Compuestos y métodos para reducir la expresión de kcnt1 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20220177893A1 (https=) |
| EP (1) | EP3938514A4 (https=) |
| JP (2) | JP7564817B2 (https=) |
| KR (1) | KR20210141983A (https=) |
| CN (3) | CN113661241A (https=) |
| AU (1) | AU2020241693B2 (https=) |
| BR (1) | BR112021015494A2 (https=) |
| CA (1) | CA3133247A1 (https=) |
| CL (1) | CL2021002398A1 (https=) |
| CO (1) | CO2021013371A2 (https=) |
| CR (1) | CR20210519A (https=) |
| IL (1) | IL285546A (https=) |
| JO (1) | JOP20210254A1 (https=) |
| MX (1) | MX2021011132A (https=) |
| PE (1) | PE20220168A1 (https=) |
| PH (1) | PH12021552220A1 (https=) |
| SG (1) | SG11202108625WA (https=) |
| TW (1) | TW202102675A (https=) |
| WO (1) | WO2020190740A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202001685TA (en) | 2017-08-28 | 2020-03-30 | Enanta Pharm Inc | Hepatitis b antiviral agents |
| IL283190B2 (en) | 2018-11-21 | 2025-08-01 | Enanta Pharm Inc | Functionalized heterocycles as antiviral agents |
| WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| EP4441229A1 (en) * | 2021-12-01 | 2024-10-09 | Atalanta Therapeutics, Inc. | Compositions and methods for treatment of epilepsies |
| IL326478A (en) * | 2023-08-16 | 2026-04-01 | Servier Lab | Oligonucleotides for modulation of KCNT1 expression |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050288242A1 (en) * | 2001-05-18 | 2005-12-29 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA) |
| US7601501B2 (en) | 2006-08-11 | 2009-10-13 | The Scripps Research Institute | Controlling osteogenesis by inhibition of osteogenic suppressors |
| CA2817256A1 (en) * | 2010-11-12 | 2012-05-18 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
| TW202246503A (zh) | 2013-07-19 | 2022-12-01 | 美商百健Ｍａ公司 | 用於調節τ蛋白表現之組合物 |
| US20200129538A1 (en) * | 2017-06-13 | 2020-04-30 | The Florey Institute Of Neuroscience And Mental Health | Compositions and methods for treating conditions associated with gain-of-function mutations in kcnt1 |
-
2020
- 2020-03-13 CR CR20210519A patent/CR20210519A/es unknown
- 2020-03-13 PH PH1/2021/552220A patent/PH12021552220A1/en unknown
- 2020-03-13 EP EP20773689.3A patent/EP3938514A4/en active Pending
- 2020-03-13 US US17/437,507 patent/US20220177893A1/en not_active Abandoned
- 2020-03-13 CN CN202080020884.0A patent/CN113661241A/zh active Pending
- 2020-03-13 JP JP2021555448A patent/JP7564817B2/ja active Active
- 2020-03-13 CN CN202511762645.3A patent/CN121674396A/zh active Pending
- 2020-03-13 CN CN202311150264.0A patent/CN117106778A/zh active Pending
- 2020-03-13 AU AU2020241693A patent/AU2020241693B2/en not_active Ceased
- 2020-03-13 CA CA3133247A patent/CA3133247A1/en active Pending
- 2020-03-13 SG SG11202108625WA patent/SG11202108625WA/en unknown
- 2020-03-13 MX MX2021011132A patent/MX2021011132A/es unknown
- 2020-03-13 BR BR112021015494-9A patent/BR112021015494A2/pt unknown
- 2020-03-13 PE PE2021001518A patent/PE20220168A1/es unknown
- 2020-03-13 WO PCT/US2020/022680 patent/WO2020190740A1/en not_active Ceased
- 2020-03-13 KR KR1020217032716A patent/KR20210141983A/ko not_active Withdrawn
- 2020-03-16 TW TW109108639A patent/TW202102675A/zh unknown
-
2021
- 2021-08-11 IL IL285546A patent/IL285546A/en unknown
- 2021-09-14 CL CL2021002398A patent/CL2021002398A1/es unknown
- 2021-09-14 JO JOP/2021/0254A patent/JOP20210254A1/ar unknown
- 2021-10-06 CO CONC2021/0013371A patent/CO2021013371A2/es unknown
-
2024
- 2024-09-27 JP JP2024168231A patent/JP2025000805A/ja active Pending
-
2025
- 2025-06-27 US US19/252,993 patent/US20250320505A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020190740A1 (en) | 2020-09-24 |
| CR20210519A (es) | 2021-11-24 |
| CN117106778A (zh) | 2023-11-24 |
| SG11202108625WA (en) | 2021-09-29 |
| CN121674396A (zh) | 2026-03-17 |
| CN113661241A (zh) | 2021-11-16 |
| TW202102675A (zh) | 2021-01-16 |
| JP7564817B2 (ja) | 2024-10-09 |
| JP2022526267A (ja) | 2022-05-24 |
| AU2020241693B2 (en) | 2024-01-04 |
| BR112021015494A2 (pt) | 2021-10-05 |
| US20250320505A1 (en) | 2025-10-16 |
| CL2021002398A1 (es) | 2022-06-03 |
| JP2025000805A (ja) | 2025-01-07 |
| CA3133247A1 (en) | 2020-09-24 |
| PH12021552220A1 (en) | 2022-05-30 |
| MX2021011132A (es) | 2021-10-14 |
| US20220177893A1 (en) | 2022-06-09 |
| AU2020241693A1 (en) | 2021-09-02 |
| EP3938514A4 (en) | 2023-05-03 |
| EP3938514A1 (en) | 2022-01-19 |
| PE20220168A1 (es) | 2022-01-28 |
| IL285546A (en) | 2021-09-30 |
| KR20210141983A (ko) | 2021-11-23 |
| JOP20210254A1 (ar) | 2023-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021013371A2 (es) | Compuestos y métodos para reducir la expresión de kcnt1 | |
| RU2020119390A (ru) | Применение каннабиноидов при лечении приступов, связанных с синдромом леннокса-гасто | |
| CO2020015256A2 (es) | Compuestos y métodos para la reducción de la expresión de lrrk2 | |
| ECSP24044340A (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp | |
| CO2019003729A2 (es) | Compuestos y métodos para reducir de la expresión de atxn3 | |
| CL2021002935A1 (es) | Células t genomodificadas | |
| BR112015014729A2 (pt) | estrutura côncava, colheitadeira e método de processamento de uma cultura agrícola | |
| AR077448A1 (es) | Uno o una combinacion de fito-canabinoides en el tratamiento de epilepsia | |
| MX2020011911A (es) | Compuestos y metodos para reducir de la expresion de atxn3. | |
| ECSP11011026A (es) | Agonistas de los receptores de la melanocortina | |
| UY38626A (es) | Compuestos y métodos para modular ube3a-ats | |
| CL2007001228A1 (es) | Uso de una composicion que contiene por lo menos un ciclopropeno para mejorar el rendimiento de una cosecha de una pluralidad de plantas, con la condicion que cuando dichas plantas comprendan manzanos, dicha composicion no contenga aminoetoxivinilgli | |
| CL2024000541A1 (es) | Compuestos y métodos para modular el scn2a | |
| UY39297A (es) | Compuestos y métodos para reducir la expresión de kcnt1 | |
| CO2021012267A2 (es) | Composiciones de materia con actividad para eliminar lipofuscina de células retinales | |
| AR122744A1 (es) | Compuestos y métodos para reducir la expresión de kcnt1 | |
| Armed Forces Health Surveillance Center (AFHSC | Erectile dysfunction among male active component service members, US Armed Forces, 2004-2013 | |
| ECSP088578A (es) | Enzimas para estrés inmunológico reducido | |
| WO2018039751A3 (en) | Feeder device | |
| CU24418B1 (es) | Una cinta de alimentación para una cosechadora de caña de azúcar | |
| EA202192527A1 (ru) | Соединения и способы для снижения экспрессии kcnt1 | |
| MX2024004323A (es) | Pectina de remolacha azucarera. | |
| Khan | N-nitro-L-arginine, a nitric oxide synthase inhibitor, aggravates iminodipropionitrile-induced neurobehavioral and vestibular toxicities in rats | |
| WO2016161343A3 (en) | Treatment for mitochondrial diseases | |
| AR118517A1 (es) | Compuestos y métodos para modular ube3a-ats |